IMP3 and triple-negative breast carcinoma: IMP3 epitopes, based on their immunogenicity (i.e., the capacity to induce a strong and specific anti-tumor immune response), could be the target for the newly synthesized vaccine for the treatment of triple negative breast cancer.[33–35] Cancer vaccines are designed to target only cancer cells and provide sparing of surrounding healthy tissue.